Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ANAPTYSBIO, INC (ANAB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update"
05/11/2023 8-K Quarterly results
Docs: "AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update"
03/01/2023 8-K Quarterly results
Docs: "AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
11/08/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
03/07/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates"
08/09/2021 8-K Quarterly results
Docs: "AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates"
05/04/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates"
08/10/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
11/08/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates"
02/27/2019 8-K Quarterly results
Docs: "AnaptysBio Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Pipeline Updates"
11/08/2018 8-K Quarterly results
Docs: "AnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates"
08/07/2018 8-K Quarterly results
Docs: "AnaptysBio Announces Second Quarter 2018 Financial Results and Provides Pipeline Updates"
05/08/2018 8-K Quarterly results
Docs: "AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates Positive Phase 2a Proof-of-Concept Data Reported from ANB020 Trials in Atopic Dermatitis and Peanut Allergy Top-Line Phase 2a Data from ANB020 in Eosinophilic Asthma Expected in the Third Quarter of 2018 SAN DIEGO, - AnaptysBio, Inc. , a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the first quarter ended March 31, 2018 and provided pipeline updates. “During the first quarter of 2018, we made significant progress in clinical development of our first-in-class antibody therapeutics for patients with severe inflammatory conditions,” said Hamza Suria, president and chief executi..."
03/05/2018 8-K Quarterly results
Docs: "AnaptysBio Announces Fourth Quarter and Full Year 2017 Financial Results and 2018 Pipeline Milestones ANB020 Top-Line Phase 2a Readouts Anticipated For Peanut Allergy in March 2018 and Eosinophilic Asthma in Second Quarter 2018 ANB019 GPP and PPP Phase 2 Studies to be Initiated During 2018 SAN DIEGO, - AnaptysBio, Inc. , a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the fourth quarter and year ended December 31, 2017 and anticipated 2018 pipeline milestones. “AnaptysBio made significant progress on multiple program and corporate milestones during 2017,” said Hamza Suria, president and chief executive officer of AnaptysBio. “We are poised to continue advancing ..."
08/10/2017 8-K Quarterly results
Docs: "ANAPTYSBIO ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES Enrollment Completed in ANB020 Phase 2a Trial for Atopic Dermatitis Multiple Top-Line Clinical Data Readouts Expected in Second Half of 2017 SAN DIEGO, August 10, 2017 - AnaptysBio, Inc. , a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today provided pipeline updates and reported second quarter 2017 financial results. “Throughout the first half of 2017, we made significant progress in the clinical development of our wholly-owned ANB020 and ANB019 clinical development programs, which are first-in-class antibody therapeutics for patients with severe inflammatory conditions,” said Hamza Suria, president and chief..."
05/11/2017 8-K Quarterly results
Docs: "ANAPTYSBIO ANNOUNCES FIRST QUARTER 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE"
03/08/2017 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy